Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Forecast 2029: Size, Share, and Competitive Landscape
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Is The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Expected To Grow In Terms Of Size?
The market size for ornithine transcarbamylase deficiency (otc deficiency) has seen significant growth in the past few years. It is projected to expand from $0.83 billion in 2024 to $0.89 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. The growth experienced in the previous period can be credited to the rise in awareness of rare metabolic disorders, enhancements in genetic screening and diagnostics methodologies, bettered neonatal screening initiatives, an increase in the occurrence of genetic testing in rare ailments, and the improvement of neonatal screening programs.
Expectations are high for robust expansion in the ornithine transcarbamylase deficiency (otc deficiency) market in the coming years. Projected to reach $1.15 billion by 2029, it boasts a compound annual growth rate (CAGR) of 6.8%. This forecasted growth can be due to factors such as heightened awareness and diagnoses, an increasing occurrence of urea cycle disorders, intensified attention on treating unusual diseases, rising research and clinical trials, along with improved patient accessibility to therapies. Significant trends in the forecast period encompass the advancement in genetic and gene editing therapies, the progression of enzyme replacement therapies, cooperative research efforts and partnerships, technological progression in diagnostic tools, and government funding and incentives for orphan drugs.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22084&type=smp
What Market Forces Are Contributing To The Growth Of The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
The expansion of the ornithine transcarbamylase deficiency market in the future is predicted to be propelled by the increasing interest in gene therapies. Gene therapy, a medical technique or treatment that modifies or manipulates an individual’s genetic material for disease treatment or prevention, is seeing an upsurge in demand due to the escalating prevalence of genetic disorders. These disorders usually have limited therapies available, and gene therapy offers an innovative way to target the problem at its source instead of mere symptom management. By rectifying the genetic mutation that impairs the urea cycle, gene therapies showcase potential for ornithine transcarbamylase deficiency, providing a targeted treatment that reinstates metabolic functions and inhibits toxic ammonia accumulation. For instance, the American Society of Gene & Cell Therapy confirmed in January 2024 that Q4 2023 saw a 10% increase in Phase III gene therapies from the previous quarter— a significant uplift since Q3 2022. With this in mind, it’s clear that the escalating demand for gene therapies is propelling the ornithine transcarbamylase deficiency growth.
How Is The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Segmented Across Key Categories?
The ornithine transcarbamylase deficiency (otc deficiency)market covered in this report is segmented –
1) By Product Type: DTX-301; SEL-313; SHP-641; PRX-OTC
2) By Treatment Type: Gene Therapy; Liver Transplant; Dietary Management; Other Treatement Type
3) By Diagnosis: Genetic Testing; Ammonia Level Testing
4) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End Users
Subsegments:
1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy; Intravenous Dosing Formulation
2) By SEL-313: Immune Tolerance-Inducing Therapy; Enzyme Replacement Therapy (ERT) Combination
3) By SHP-641: Small Molecule Therapy; mRNA-Based Therapeutic Approach
4) By PRX-OTC: Recombinant Enzyme Replacement Therapy; Protein Engineering-Based Therapy
What Current And Upcoming Trends Are Shaping The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
Key players in the ornithine transcarbamylase deficiency (OTC Deficiency) market are prioritizing the development of innovative treatments like mRNA therapeutics aimed at improving treatment effectiveness and targeting the genetic root of OTC deficiency. mRNA therapeutics utilize messenger RNA to direct cells to produce specific therapeutic proteins, harnessing the body’s natural protein synthesis to treat various conditions including genetic diseases, infections, and cancers. For example, in June 2023, Arcturus Therapeutics Holdings Inc., a US biotech firm, earned Fast Track Designation from the FDA for its mRNA therapeutic candidate ARCT-810 for OTC deficiency. This designation aims to speed up the drug’s development and review, offering benefits such as more frequent FDA communication and priority evaluation. ARCT-810 seeks to enable patients with this urea cycle disorder to generate functional OTC enzyme in liver cells, tackling the disease’s underlying cause and potentially enhancing their quality of life.
Who Are The Major Stakeholders Operating In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market?
Major companies operating in the ornithine transcarbamylase deficiency (OTC deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.
Access The Complete Report Here:
How Do Regional Dynamics Influence The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Performance?
North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ornithine transcarbamylase deficiency (OTC deficiency) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=22084&type=smp
Browse Through More Reports Similar to the Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market 2025, By The Business Research Company
5 Alpha Reductase Deficiency Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/5-alpha-reductase-deficiency-global-market-report
Iron Deficiency Injectable Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
Alpha 1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
